Routine prophylaxis with Esperoct® reduces the frequency of bleeding episodes.
As a prophylaxis: Dose less oftena without sacrificing protection.
aCompared to SHL products, 50% fewer infusions when administered every other day and 40% fewer when administered 3x weekly.
b175 PTPs with severe hemophilia A received Esperoct® 50 IU/kg every 4 days for 76 weeks based on median annualized bleed rates shown.
cData shown are from a study of 68 previously treated children (34 aged 0–5 and 34 aged 6–11) who received an average dose of approximately 65 IU/kg twice weekly for 26 weeks. Median annualized bleeding rates are shown.
On-demand: The bleed control you count on.
The effectiveness of Esperoct® for on-demand treatment and control of hemophilia A was shown in a study of adults and adolescents.
of bleeds controlled with 1-2 infusionsd
dData shown are from a study where 12 adult and adolescent PTPs with severe hemophilia chose to be treated on demand and received Esperoct® for 532 bleeding episodes.
In surgery: Esperoct® is there when you need it.
From tooth extraction to joint replacement, count on extended half-life Esperoct® to help control the bleeding.
eBased on a 4.0 scale of excellent, good, moderate and none.
Your questions, answered.
Question: How is it possible to dose less often while maintaining higher factor levels?
Answer: Esperoct® is an extended half-life (EHL) factor. In a study of adults and adolescents treated with Esperoct® for prophylaxis, researchers confirmed that the recombinant stays in the body longer than standard half-life products.f And that typically means dosing less often. This EHL, in combination with the ability of Esperoct® to keep factor levels in adults at or above 3% for 100% of the timeg, leads to effective bleed protection.
Question: How is Esperoct® used for surgery?
Answer: The number of doses and length of treatment varies by both procedure and patient. Your hematologist and surgeon will work together to create the best treatment plan for your circumstances.
fData shown are from a comparison study of 26 previously treated patients (PTPs) 18 years or older who received a 25, 50, or 75 IU/kg dose of their previous SHL product followed by the same dose of Esperoct®. To allow for comparison, all results were adjusted to a 50 IU/kg dose of each product.
gData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.